A model study estimating the potential impact of increased use of sodium channel blockers (SCBs) among patients with partial-onset seizures suggests significant reductions in costs, according to data presented at the 2015 annual meeting of the American Academy of Neurology.
Two cross-sectional studies of the decision-making process, insurance coverage and disease-modifying therapy (DMT) choices of patients with multiple sclerosis, provide glimpses of patients’ preferences.
The analgesic effects of tramadol (Ultram), 1 of the 5 most often prescribed opioids in the world, may be sex-dependent, according to a study presented at the 2015 American Academy of Pain Medicine annual meeting.
Patients with secondary-progressive multiple sclerosis (SPMS) have to endure more than just declining physical and cognitive function.
Until recently, the selection of patients for aggressive pain control therapy, including high-dose opioids and implanted delivery systems, has mostly been done on a subjective basis.
In the treatment of chronic nonmalignant pain, patient-specific factors, especially household income, more accurately predicted quality-of-life outcomes than opioid use, according to a study presented at the 2015 American Academy of Neurology annual meeting.
Page 3 of 3
Results 21 - 26 of 26
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology